Abstract
Recommendations for the clinical use of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT) imaging have become available [1] and the imaging technique has been incorporated into the management algorithms recommended by the National Comprehensive Cancer Center Network (NCCN) [2]. Procedures and practice guidelines have been published by the Society of Nuclear Medicine (SNM) and the American College of Radiology (ACR) [3–5]. Recommendations in National Cancer Institute (NCI) clinical trials are also available [6]. For patients with lymphoma, consensus recommendations for assessing response have been published by the imaging subcommittee of the International Harmonization Project, including criteria for interpretation [7]. Response criteria for lymphoma have been revised based on PET/CT imaging, eliminating the “complete remission unconfirmed (CRu)” category [8].
Keywords
- Standard Uptake Value
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Autologous Stem Cell Transplant
- Indolent Lymphoma
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Podoloff DA, Advani RH, Allred C et al (2007) NCCN Task Force Report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 5(Suppl 1):S1–S22
Fletcher JW, Djulbegovic B, Soares HP et al (2008) Recommendations for the Use of FDG (fluorine-18, (2-[18F]fluoro-2-deoxy-D-glucose) positron emission tomography in Oncology. J Nucl Med 49:480–508
Coleman RE, Delbeke D, Guiberteau MJ et al (2005) Intersociety dialogue on concurrent PET-CT with an integrated imaging system: From the Joint ACR/SNM/SCBT-MR PET-CT Working Group. J Nucl Med 46:1225–1239
Delbeke, Coleman RE, Guiberteau MJ et al (2006) Society of Nuclear Medicine procedure guidelines for tumor imaging using FDG PET/CT. J Nucl Med 47:885–895
American College of Radiology (2007) ACR practice guidelines for performing FDG PET/CT in oncology. www.ACR.org
Shankar LK, Hoffman JM, Bacharach S et al (2006) National Cancer Institute. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059–1066
Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578
Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586
Hutchings M, Loft A, Hansen M et al (2006) Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 24:146–150
National Cancer Institute: http://www.cancer.gov/cancer-topics/Topic “Staging”
Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849
Ping Lu (2005) Staging and classification of lymphoma. Semin Nucl Med 35:160–164
Schoder H, Noy A, Gonen M et al (2005) Intensity of 18-fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23:4643–4651
Elstrom R, Guan L, Baker G et al (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875–3876
Tsukamoto N, Kojima M, Hasegawa M et al (2007) The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-PET with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652–659
Brepoels L, Stroobants S, De Wever W et al (2008) Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 49:1693–1701
Kako S, Izutsu K, Ota Y et al (2007) T-cell FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685–1690
Jerusalem G, Beguin Y, Najjar F et al (2001) Positron emission tomography (PET) with 18F-fiuorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 12:825–830
Bruzzi JF, Macapinlac H, Tsimberidou AM et al (2006) Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47:1267–1273
Najjar F, Hustinx R, Jerusalem G et al (2001) Positron emission tomography (PET) for staging low-grade non-Hodgkin’s lymphomas (NHL). Cancer Biother Radiopharm 16:297–304
Hoffmann M, Kletter K, Becherer A et al (2003) 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64:336–340
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994
Solal-Céligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265
Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514
Okada J, Oonishi H, Yoshikawa K et al (1994) FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 8:187–191
Israel O, Keidar Z, Bar-Shalom R (2004) Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 34:166–179
Seam P, Juweid ME, Cheson BD (2007) The role of FDG-PET scans in patients with lymphoma. Blood 110:3507–3516
Buchmann I, Reinhardt M, Eisner K et al (2001) 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91:889–899
Isasi CR, Lu P, Blaufox MD (2005) A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066–1074
Thill R, Neuerburg J, Fabry U et al (l 997) Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 36:234–239
Moog F, Bangerter M, Diederichs CG et al (1998) Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206:475–481
Moog F, Bangerter M, Kotzerke J et al (1998) 18-F-fluo-rodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603–609
Carr R, Barrington SF, Madan B et al (1998) Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91:3340–3346
Pakos EE, Fotopoulos AD, Ioannidis JP (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46:958–963
Schaefer NG, Hany TF, Taverna C et al (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging — do we need contrast-enhanced CT? Radiology 232:823–829
Raanani P, Shasha Y, Perry C et al (2006) Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 17:117–122
Rodríguez-Vigil B, Gómez-León N, Pinilla I et al (2006) PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47:1643–1648
Hicks RJ, MacManus MP, Seymour JF (2005) Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 35:165–175
Bangerter M, Kotzerke J, Griesshammer M et al (1999) Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 38:799–804
Cremerius U, Fabry U, Neuerburg J et al (1998) Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 19:1055–1063
Spaepen K, Mortelmans L (2001) Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin’s lymphoma and Hodgkin’s disease. Q J Nucl Med 45:269–273
Cheson BD, Horning SJ, Coiffier B (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
Juweid ME, Wiseman GA, Vose JM et al (2005) Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652–4661
Jerusalem G, Beguin Y, Fassotte MF et al (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433
Mikhaeel NG, Timothy AR, O’Doherty MJ et al (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin’s Lymphoma-comparison with CT. Leuk Lymphoma 39:543–553
Jerusalem G, Hustinx R, Beguin Y, Fillet G (2005) Evaluation of therapy for lymphoma. Semin Nucl Med 35:186–196
Terasawa T, Nihashi T, Hotta T, Nagai H (2008) 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive Non-Hodgkin’s lymphoma: a systematic review. J Nucl Med 49:13–21
Kelloff GJ, Sullivan DM, Wilson W et al (2007) FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol 14:330–339
Kazama T, Faria SC, Varavithya V et al (2005) FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 25:191–207
Abdel-Dayem HM, Rosen G, El-Zeftawy H et al (1999) Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation. Clin Nucl Med 24:319–322
Gundlapalli S, Ojha B, Mountz JM (2002) Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma. Clin Nucl Med 27:140–141.
Ferdinand B, Gupta P, Kramer EL (2004) Spectrum of thymic uptake at 18F-FDG PET. Radiographics 24:1611–1616
Joyce JM, Degirmenci B, Jacobs S et al (2005) FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy. Clin Nucl Med 30: 564–568
Ulaner GA, Colletti PM, Conti PS (2008) B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy—initial experience. Radiology 246: 895–902
Zinzani PL, Tani M, Fanti S et al (2008) A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 19:769–773
Johnston PB, Wiseman GA, Micallef IN (2008) Positron emission tomography using F-18 fluorodeoxyglucose pre-and post-autologous stem cell transplant in non-Hodgkin’s lymphoma. Bone Marrow Transplant 41:919–925
Schot BW, Zijlstra JM, Sluiter WJ et al (2007) Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109:486–491
Filmont JE, Gisselbrecht C, Cuenca X (2007) The impact of pre-and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 110:1361–1369
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Italia
About this chapter
Cite this chapter
Delbeke, D. (2011). Lymphoma: Differential Diagnosis of Mediastinal Masses and Response. In: Hodler, J., von Schulthess, G.K., Zollikofer, C.L. (eds) Diseases of the Heart and Chest, Including Breast 2011–2014. Springer, Milano. https://doi.org/10.1007/978-88-470-1938-6_28
Download citation
DOI: https://doi.org/10.1007/978-88-470-1938-6_28
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1937-9
Online ISBN: 978-88-470-1938-6
eBook Packages: MedicineMedicine (R0)